-
Avelumab, sold
under the
brand name Bavencio, is a
fully human monoclonal antibody medication for the
treatment of
Merkel cell carcinoma,
urothelial carcinoma...
- non-small cell lung cancer.
Avelumab (Bavencio) is a
fully human IgG1
antibody developed by
Merck Serono and Pfizer.
Avelumab is FDA
approved for the treatment...
- was
approved for
medical use in the
United States in
September 2024.
Avelumab, sold
under the
brand name Bavencio, is a
fully human monoclonal antibody...
-
Retifanlimab Toripalimab PD-L1
inhibitorsTooltip Programmed death-ligand 1 BMS-202
Atezolizumab Avelumab Durvalumab KN035
Cosibelimab AUNP12 CA-170 BMS-986189...
- studied.
Dostarlimab exhibits better efficacy than PD-L1 inhibitors, such as
avelumab and durvalumab, in dMMR
advanced endometrial cancers.
Efficacy of the drug...
-
Retifanlimab Toripalimab PD-L1
inhibitorsTooltip Programmed death-ligand 1 BMS-202
Atezolizumab Avelumab Durvalumab KN035
Cosibelimab AUNP12 CA-170 BMS-986189...
- BMS-936559 (Bristol
Myers Squibb). Both
atezolizumab (MPDL3280A, Roche) and
avelumab (Merck KGaA, Darmstadt,
Germany and Pfizer)
target the
similar PD-L1 receptor...
-
Retifanlimab Toripalimab PD-L1
inhibitorsTooltip Programmed death-ligand 1 BMS-202
Atezolizumab Avelumab Durvalumab KN035
Cosibelimab AUNP12 CA-170 BMS-986189...
-
small cell lung cancer,
hepatocellular carcinoma,
metastatic melanoma Avelumab Bavencio Merck KGaA and
Pfizer PD-L1 2017
Merkel cell carcinoma, urothelial...
-
Retifanlimab Toripalimab PD-L1
inhibitorsTooltip Programmed death-ligand 1 BMS-202
Atezolizumab Avelumab Durvalumab KN035
Cosibelimab AUNP12 CA-170 BMS-986189...
